Sunesis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Sunesis and buy or sell other stocks, ETFs, and their options commission-free!About SNSS
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.
CEOMark A. Rothera, MBA
CEOMark A. Rothera, MBA
Employees—
Employees—
HeadquartersCardiff, California
HeadquartersCardiff, California
Founded1998
Founded1998
Employees—
Employees—
SNSS Key Statistics
Market cap388.70K
Market cap388.70K
Price-Earnings ratio-0.01
Price-Earnings ratio-0.01
Dividend yield—
Dividend yield—
Average volume491.85K
Average volume491.85K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.58
52 Week high$0.58
52 Week low$0.008
52 Week low$0.008
Stock Snapshot
Sunesis(SNSS) stock is priced at $9.19, giving the company a market capitalization of 388.7K. It carries a P/E multiple of -0.01.
Sunesis(SNSS) stock opened on 2026-03-12 at —. The price climbed to — and dipped to —.
Sunesis(SNSS) shares are trading with a volume of 0, against a daily average of 491.85K.
In the last year, Sunesis(SNSS) shares hit a 52-week high of $0.58 and a 52-week low of $0.01.
In the last year, Sunesis(SNSS) shares hit a 52-week high of $0.58 and a 52-week low of $0.01.
People also own
Based on the portfolios of people who own SNSS. This list is generated using Robinhood data, and it’s not a recommendation.